Randomised controlled trial testing the efficacy of a smartphone application designed to improve the mental health and wellbeing of doctors in training

Not Applicable

Recruiting

• Conditions: Depression; Mental Health - Depression

• Registration Number: ACTRN12623000664640
• Lead Sponsor: SW Sydney

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-06-20
• Last Update Posted: 29 April 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 778

Inclusion Criteria

Inclusion criteria for participants taking part in this study includes:

1.Willing to provide consent to participate
2.Currently employed as a doctor in training in Australia (interns, hospital medical officers, resident medical officers, non-accredited trainees, postgraduate trainees, principal house officers, registrars, and specialist trainees. Career medical officers who intend to undertake further postgraduate training in medicine can also participate.)
3.Ownership of an internet-enabled smartphone that has an Apple or Android operating system

Exclusion Criteria

Candidates will be excluded from the study if they:
-Do not provide consent to participate, or
-Are not currently employed as a doctor in training in Australia, or
-Do not own an internet-enabled smartphone with an Apple or Android operating system.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Depression symptom change: <br>Depression will be measured using the Patient Health Questionnaire (PHQ-9), a reliable and valid nine-item screening tool to assess depression severity over the past fortnight. The PHQ-9 also includes a single item assessing level of difficulty in daily functioning due to depressive symptoms. [ Depression symptoms will be assessed at baseline, at post-completion of intervention (the post-completion of intervention questionnaire becomes available 1 month post-baseline for intervention group participants and 4 months post-baseline for waitlist control participants), and at 3 months post-baseline. The primary timepoint will be at 1 month post-baseline, which both the experimental and waitlist control participants will be asked to respond to.]